is a major cause of nephrotic syndrome of origin in adults. It is the second or third leading cause of end-stage renal disease in patients with primary glomerulonephritis, and is the leading glomerulopathy that recurs after (occurring in about 40% of patients).
circulating directed against endogenous antigens on or near podocyte foot processes form immune complexes C5b-9 (MAC) causes silt diaphragm protein disruption redistribution of actin GBM expansion by injured podocytes.
Data from the first 2,935 patients consented to the CKD.QLD registry across five sites was analysed, with a comparison between those with and without Genetic (GRD). QLD registry, national census data and extracted Australian and New Zealand Dialysis and (ANZDATA) registry report data respectively
Treatments include: Observation for patients with asymptomatic proteinuria therapy for progressive disease or symptomatic nephrotic syndrome - Chlorambucil, cyclosporine, tacrolimus, cyclophosphamide Corticosteroids - not effective when used alone, but used in combination with immunosuppressants Diuretics - may be used in situation of volume overload".
Major research on disease:
Clinicopathological analysis of idiopathic membranous nephropathy in young adults. Develop proprietary assays for the identified biomarkers and assess their diagnostic and predictive values in large cohorts.